NasdaqGS:GILDBiotechs
Positive Lenacapavir HIV Data And Governance Shift Might Change The Case For Investing In Gilead (GILD)
Gilead Sciences recently reported that its Phase 3 ARTISTRY-2 trial showed a once-daily bictegravir/lenacapavir pill matched Biktarvy in maintaining HIV viral suppression at Week 48 with no new safety concerns.
Alongside these lenacapavir data, the promotion of long-time Gilead lawyer Keeley Wettan to Executive Vice President, General Counsel, Legal & Compliance underscores how central this medicine has become to the company’s portfolio and governance priorities.
We’ll now explore how these...